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Abstract
Background: Lifestyle and dietary changes reflect an ongoing epidemiological transition in China, with cardiovascular
disease (CVD) playing an ever-increasing role in China’s disease burden. This study assessed the burden of CVD and the
potential value of lipid and blood pressure control strategies in China.
Methods: We estimated the likely burden of CVD between 2016 and 2030 and how expanded use of lipid lowering
and blood pressure control medication would impact that burden in the next 15 years. Accounting for the costs of
drug use, we assessed the net social value of a policy that expands the utilization of lipid and blood pressure lowering
therapies in China.
Results: Rises in prevalence of CVD risk and population aging would likely increase the incidence of acute myocardial
infarctions (AMIs) by 75 million and strokes by 118 million, while the number of CVD deaths would rise by 39 million in
total between 2016 and 2030. Universal treatment of hypertension and dyslipidemia patients with lipid and
blood pressure lowering therapies could avert between 10 and 20 million AMIs, between 8 and 30 million
strokes, and between 3 and 10 million CVD deaths during the 2016–2030 period, producing a positive social
value net of health care costs as high as $932 billion.
Conclusions: In light of its aging population and epidemiological transition, China faces near-certain increases
in CVD morbidity and mortality. Preventative measures such as effective lipid and blood pressure management may
reduce CVD burden substantially and provide large social value. While the Chinese government is implementing more
systematic approaches to health care delivery, prevention of CVD should be high on the agenda.
Keywords: Cardiovascular disease, Social value, Epidemiology, Lipids, Blood pressure, China
Background
The consequences of population aging in China are
likely to be exacerbated by the rising prevalence of
chronic, non-communicable diseases. The bulk of dis-
ease burden in China has shifted away from infectious
diseases and reproductive complications in the last two
decades, [1] with the prevalence of non-communicable
diseases rising rapidly and now accounting for over 80 %
of the overall disease burden [2]. Cardiovascular disease
(CVD) plays the leading role among the set of non-
communicable diseases, with stroke, ischemic heart dis-
ease, and chronic obstructive pulmonary disease as the
leading causes of death in China in 2010 [1]. About 230
million patients, or approximately one in five adults in
China, suffer from CVD [3]. The Global Burden of
Disease reported that stroke was the leading cause of
death in China in 2010, with coronary heart disease
(CHD) close behind and gaining ground [4, 5]. In
general, the CVD burden in China is expected to rise as
the Chinese population becomes more sedentary and
diets become more geared towards red meat, sugars, and
saturated fats [3].* Correspondence: warren.stevens@pheconomics.com
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Evidence of this epidemiological transition has already
been highlighted in China, [6] most recently with the aid
of the Global Burden of Disease series [1]. These studies
suggest that the proportion of total deaths attributable
to CVD is rising at approximately 2 % annually, more
quickly in urban areas than in rural areas [6]. The stud-
ies also highlight that although age is a strong predictor
of CHD risk, the total increase in mortality rates is
greater than the increase in mortality rates attributable
solely to aging. The age-standardized CHD mortality
rate has been rising at 1 % annually in the last decade,
which accounts for about half of the total increase in
mortality rates.
Although CVD factors in China are approaching those
in Western nations, the use of primary and secondary
prevention technologies has lagged behind that of the
US and Europe, which have seen declines in CVD deaths
partly due to expanded use of evidence-based CVD
therapies [7]. In addition, the benefits of better CVD
screening and prevention have not been realized in
China. For example, around 30 % of hypertension in the
Chinese population remains undiagnosed, [8] which is
almost four times the corresponding rate in the US [9].
However, this suggests that Chinese health policymakers
are presented with a major opportunity to prevent CVD
by using one or more available prevention approaches.
This was recognized by the Chinese government in a
recent policy report suggesting that impending health
policy reforms should highlight a shift from a health
system that has traditionally been treatment-based to-
wards one which has a greater emphasis on primary and
secondary prevention [10].
A number of health care technologies and public health
interventions have been shown to be successful in slowing
the rise in the burden of CVD in industrialized countries.
Systematic reviews demonstrate that prevention strategies
for CHD and heart failure reduce hospital admissions;
[11] enhance quality of life; [11, 12] improve health out-
comes; [12–15] and reduce healthcare costs [12]. While
some reviews have reported uncertainty about survival
improvement; [11] recurrent cardiovascular incidents; [11]
and cost effectiveness; [11, 12] others have seen statisti-
cally significant improvement in mortality; [16] cardiac
events; [16] and gains in cost per quality-adjusted life
years [15].
In addition to the more widely accepted use of blood
pressure medication in China, statins have been shown
to have a major impact on reducing CVD burden in
many other countries [17]. The efficacy of statins in low-
ering the risk of cardiovascular events is well recognized
around the world [18–21]. The EVANS study in France
found that if statin-treated patients discontinued use,
4992 major cardiovascular events and 1159 deaths would
occur in the first year after discontinuation [20]. The
cost effectiveness of statins has varied across studies
depending on the drug price and the patient’s level of
risk. In general, patients who have higher baseline car-
diovascular risk recoup comparably larger health and
economic benefits [22–25]. Moreover, as the price of the
drug falls, the cost-effectiveness of statins improves
across all risk groups [25, 26]. Despite this, the current
use of statins in low-income countries remains low. Ac-
cording to the Prospective Urban Rural Epidemiological
study, the level of statin use was just 1.7 % in China, much
lower than levels in the US and Europe (50–60 %) [27].
The Chinese government is currently working towards
a more systematic approach to managing hypertension
and diabetes. However, healthcare professionals and ad-
ministrators only recently began to pay more attention
to hyperlipidemia. Epidemiological transition theory [4]
and recent evidence of growth in cholesterol levels [28]
suggest that this is about to change. The current stage of
evolution of the Chinese healthcare system presents a
unique opportunity to intervene, due to its near univer-
sal health insurance coverage, the introduction of the
New Rural Cooperative Medical System in 2003, and
other schemes for employees of private and state-owned
enterprises. Moreover, many insurance schemes in China
have annual caps on inpatient and outpatient benefits,
with coinsurance rates for inpatient care of 60 % [29].
The limits on inpatient coverage place even greater
importance on the coverage of primary and secondary
prevention. Measures aimed at improving lipid manage-
ment and CVD prevention in China should play a sig-
nificant role in this regard. While some studies have
examined the burden of CVD in China with an aging
population, there is a dearth of literature comprehensively
accounting for the impact of China’s epidemiological
transition and estimating the potential value of measures
to mitigate the rise in mortality and morbidity from non-
communicable disease. This study assessed the burden of
CVD and the potential value of lipid and blood pressure
control strategies in China.
Methods
Data sources
We obtained baseline data on age, gender, and prevalence
of risk factors from the 2009 China Health and Nutrition
Survey (CHNS), [28] a longitudinal health survey under-
taken every 2 years that contains information on the
prevalence of CVD risk factors such as hypertension,
obesity, smoking, and diabetes, as well as levels of both
high-density and low-density lipoprotein cholesterol
(LDL-C) [28]. We used the 2009 wave, because it was the
only year available with full biomarker data (sampling
weights were not available in Popkin et al. 2009). It
included almost 30,000 individuals in 15 provinces and
municipal cities in China (see Additional file 1 for a more
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detailed description of study data). Since the CHNS data
only include historical self-reported recall of CVD events,
we estimated the incidence and mortality risk of both acute
myocardial infarction (AMI) and stroke (hemorrhagic and
ischemic) from the peer-reviewed literature (see Additional
files 1, 2, and 3 for more detail). Longitudinal population
trends were modeled using the United Nations Population
Division predictions [30]. Preventative intervention effects
were modelled using the World Health Organization
(WHO) region-specific bivariate risk model [31].
Analytical approach
Our model has three components: burden estimation,
trend extrapolation, and an aversion estimation based on
intervention.
Burden model
CVD burden was divided into five age strata (35–45,
45–55, 55–65, 65–75, and 75+ where lower limits are in-
clusive) separately for males and females. We further
subdivided each of these age-sex subgroups into risk cat-
egories based on the number of metabolic syndrome
conditions (0, 1 or 2, and 3+) from which they suffered
(see Additional file 1 for metabolic syndrome definition
cut-offs). With different risk profiles stroke events were
divided into hemorrhagic stroke and ischemic stroke.
Baseline AMI and stroke mortality and incidence were
estimated from recent literature. Relative risks of CVD
events for each of our strata age * risk group * gender
were estimated using the methodology described in
Additional file 1. The absolute burden was then calcu-
lated by multiplying the relevant CVD event rates by the
age and gender stratified UN population data [30] and
distributing between risk groups using the estimated
relative risks.
Trend extrapolation
We project forward the incidence of CVD events in two
ways. First, we model the trend in CVD events that
would result from changes in the age-sex profile of the
Chinese population, holding risk factors, relative risks,
and all other factors constant. Second, we include projec-
tions of how underlying risk factors are likely to evolve in
the future.
To project changes in the demographic profile over
the next 15 years, we used United Nations Population
Division projections for the Chinese population (Fig. 1),
[30] stratified by age as shown in Additional file 1:
Figure S3.1. Under this model the risk factor prevalence
within each demographic subgroup stays constant.
Our second approach layers trends in risk factors on top
of the projected demographic changes. To estimate the fu-
ture prevalence of key risk factors, we utilized the theory
of epidemiological transition to estimate linear regression
models (using a robust regression algorithm based on
multivariate weighted least squares solution with a bis-
quare weight function) for each risk factor prevalence as a
function of gross national income per capita [32]. The
models were estimated using data from 2000–2008 for 18
Southeast Asian countries (see Additional file 1: Figures
S3.2 and S3.3 for risk factor trends) [33, 34]. This ap-
proach yields risk factor prevalence trends for each risk
factor, which was converted to the model risk groups
based on the number of subjects with 0, 1–2, or 3+ meta-
bolic syndrome conditions. The risk factor prevalences are
highly correlated, and the correlation structure was esti-
mated from the CHNS biomarker data and assumed to re-
main constant over time. With the prevalence of each risk
factor and their correlation known, subejcts’ dichotomous
disease status for each risk factor were simulated from a
multivariate binomial distribution. Using this simulated
Fig. 1 Projected rate of change in Chinese population (2016–2030). Notes: Data are based on the United Nations Population Division 2012 Project
Population Forecasts POP/DB/WPP/Rev.2012/POP/F15-1
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data, we then estimated the expected number of individ-
uals in each of the model risk categories of 0, 1–2, or 3+
conditions. A detailed description of this process is
provided in Additional file 1.
Intervention model
CHNS biomarker data were used to estimate the joint bi-
variate distribution of total cholesterol (TC) and systolic
blood pressure (SBP) within each age * condition category
for diabetic/non-diabetic and smoking/non-smoking sub-
jects. The CVD event burden for each TC * SBP cell of the
bivariate distribution within each strata was then esti-
mated using the WHO CVD risk model [31]. For each
intervention a prescription region is defined within the
bivariate TC (LDL-C) * SBP distribution. A detailed deriv-
ation of this process is described in Additional file 1.
The intervention effects were defined by two compo-
nents: the estimated average reduction in TC (LDL-C)
and/or SBP magnitude, and the effect of that reduction
on mortality and morbidity. Statins were assumed to
reduce LDL-C by 38.7 mg/dL on average, with a 25 %
reduction per 41.7 mg/dL (equivalent to 1 mmol/L) in
AMI morbidity and mortality [35]. Ischemic stroke
incidence was reduced by 20 % per 41.7 mg/dL, with no
significant reduction (5 % level) in hemorrhagic stroke.
There were no significant effects on stroke morbidity or
mortality [36].
The reduction in SBP (delta_P) was estimated using
the age-specific model, [37] where the reduction in SBP
was assumed to be:
▪ delta_P1 = 9.1 + 0.1 * (SBP-154) for one drug
▪ delta_P2 = P1 + 9.1 + 0.1 * (SBP-P1-154) for two drugs
▪ delta_P = 0.5*(P1 + P2), where SBP is the population
systolic blood pressure.
The accompanying risk in mortality and morbidity was
calculated as F(delta_P/20), where F takes the stroke
(hemorrhagic and ischemic) and AMI specific values in
Table 1 [37].
The two-dimensional risk distribution allows a simul-
taneous statin and antihypertensive prescription model.
Assuming for a particular population that PLDL-C and
PSBP were the prescription cut-off points, we modeled
the provision of statins and/or hypertensives using the
following rules:
▪ Population A: LDL-C > PLDL-C and SBP < PSBP
(statins)
▪ Population B: LDL-C < PLDL-C and SBP > PSBP
(antihypertensive)
▪ Population C: LDL-C > PLDL-C and SBP > PSBP (both)
To avoid double counting of CVD events and to account
for possible antagonism across therapies, we exploit re-
search on polypill prescriptions [38] that estimates the
total events averted as:
Events averted in Population A þ Events averted in Population B
þ Events averted from antihypertensive intervention in Population C
þ 69:8%  Events averted from statin intervention in Population C:
A flow diagram describing the three steps of burden,
trend extrapolation, and intervention/aversion is pro-
vided in Additional file 1.
Translation to net social value
In order to estimate the potential cost and value to so-
ciety as a whole, we estimated the cost of treatment for
eligible patients over the time period of the study, and
the cost savings from reduced CVD events. The mean
annual cost estimate per person-treatment for hyper-
lipidemia or hypertension was taken from the litera-
ture. To estimate the cost of statin use for each patient
over the 15-year period, we took initial estimates for an
annual supply of statins of $291 (1819 RMB) from
Zeng et al. (2013), weighted by originator drug and
generic volumes data from the same study [39]. We
multiplied this full year cost by the mean adherence
level of 75 % from statin effectiveness studies, [40] to
obtain an average prescription cost of $218 per person-
year. Studies have shown a downward trend of just
under 3 % in prices for both originator and generic sta-
tins in China recently (2004–2013) as utilization rises,
[41] which we applied to future years (see Additional
file 1 for more details).
A number of medications are used to treat blood pres-
sure including diuretics, beta-blockers, alpha-blockers,
angiotensin receptor blockers, calcium channel blockers,
and angiotensin-converting enzyme inhibitors, and on
average, the number of drugs taken by a hypertensive
patient is 1.6 [42]. We took estimates of the annual cost
of pharmaceutical treatment of hypertension from Le et
al. (2012) with a mean of $130 per year for all drugs for
each hypertensive patient in 2010 [43].
Estimates of the cost of events were also derived
from the literature. Unlike new pharmaceuticals,
these costs tend to rise over time, so we took recent
estimates of AMI and stroke costs and applied 4.6 %
annual estimate of the health care price index over
the last 5 years for China [44]. We used this figure
Table 1 Parameters for antihypertensive risk reduction model
Age 39.5 44.5 54.5 64.5 74.5 84.5 87.5
Fstroke 0.36 0.36 0.38 0.43 0.50 0.67 0.67
FAMI 0.49 0.49 0.50 0.54 0.60 0.70 0.70
Data are based on Law et al. (2009)
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over the 15 years of the model. For AMI the mean
cost was $6623 (RMB 46,365) in 2012, [40] and for
stroke the mean cost was $1602 (RMB 11,216) in
2010 [45].
In order to estimate the potential social value of the
averted CVD deaths, we considered several estimates
of the value of life from value of statistical life (VSL)
studies. Recent reviews on estimating the value of life
have suggested estimates in the range of $500,000 to
$2 million, although most of these studies have been
undertaken in Europe and North America [46]. We
found three relatively recent VSL estimates from stud-
ies undertaken in a Chinese population [47–49]. These
studies estimated a mean VSL for various Chinese
populations of 15–20 times gross domestic product
(GDP) per capita. Our life tables suggested a value of a
life year ranging from one to two times GDP per
capita. Another approach developed by the WHO
Macroeconomic Commission on Health meeting in
2000 suggests a value ranging from one to three times
GDP per capita. Therefore, for our model, we used two
times per capita GDP, which lies in the midpoint of
the full range of values described by these studies.
This results in an estimate of $13,408 per life year
saved—twice the current GDP per capita of $6704.
(Additional file 1: Appendices 8.1 and 8.2 provide sensitiv-
ity analysis of social value estimates based on varying
value of a life year at 1 and 3 times GDP per capita.)
We then used the age at death generated by the disease
burden model and the most recent life tables for the
Chinese population to generate life years lost at each
age of death. Additional file 1 shows the methodology
and the life tables we used to estimate life years saved
from premature death averted.
Results
Future burden of CVD in China
The results of the model were consistent with a num-
ber of other projections of heart disease in China and
Southeast Asia in that the burden of CVD is on the
rise, and that primary and secondary prevention are
likely to be key priorities for health policy in the near
future [1, 50]. The model predicted that the number
of AMIs is expected to rise from 4 million in 2016 to
6.1 million in 2030; strokes will rise from 6.1 million
in 2016 to 9.8 million in 2030, and total deaths from
CVD will rise from 2 million to 3.3 million per year
during the same time period, keeping all other factors
constant. Table 2 shows the total predicted number of
CVD events and deaths in China over the 2016–2030
period by age and gender.
Estimates of impact from optimal use of medication
When we applied the LDL-C shifting model, under the
assumption that all people who could benefit from lipid
lowering therapy do so, we predicted that the potential
number of AMIs that could be avoided would be be-
tween 450,000 and 850,000 per year between 2016 and
2030. In addition, between 350,000 and 700,000 strokes
and between 150,000 and 300,000 CVD deaths could be
avoided per year in 2016–2030. Similarly, when we mod-
eled the impact of optimal utilization of blood pressure
medication in the Chinese population, we predicted that
between 600,000 and 1 million AMIs could be avoided
per year, as well as between 1.2 and 2 million strokes
and between 350,000 and 600,000 deaths from CVD
could be averted in the 2016–2030 period. When we
modeled the impact of optimal coverage of both blood
pressure and lipid control medication, the resulting
Table 2 Estimates of number of AMIs, strokes and CVD deaths by gender and age (2016–2030)
35–45 45–55 55–65 65–75 Over 75
AMI incidence (2016–2030)
Male 2,733,082 5,506,290 9,434,189 11,994,178 9,030,523
Female 2,111,375 4,634,030 9,143,257 11,232,330 9,199,603
Total 4,844,457 10,140,320 18,577,446 23,226,508 18,230,126
Stroke incidence (2016–2030)
Male 3,237,421 7,371,258 14,811,925 22,241,630 25,126,874
Female 3,807,198 6,885,464 11,759,056 12,473,629 10,607,893
Total 7,044,619 14,256,722 26,570,981 34,715,259 35,734,767
CVD deaths (2016–2030)
Male 708,068 1,848,423 4,009,758 8,820,599 7,661,065
Female 205,738 651,001 2,127,829 6,476,425 6,573,086
Total 913,806 2,499,424 6,137,587 15,297,024 14,234,151
Data are based on authors’ calculations. Age strata lower limits are inclusive
AMI acute myocardial infarction, CVD cardiovascular disease
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events averted were estimated between 1 and 1.65 mil-
lion for AMIs, 1.4 to 2.5 million for strokes, and 450,000
to 850,000 for deaths from CVD that could be prevented
per year in 2016–2030. The impact on overall burden of
AMIs, strokes, and CVD deaths as compared to the total
burden are shown in Table 3 and Figs. 2, 3 and 4.
Social and economic value of comprehensive lipid control
with statins
We estimated the social value of deaths averted, the cost
of treatment net of the cost savings from events and
hospitalization averted, and the net social value (social
value net of net costs of treatment) for a series of
scenarios. We estimated the value of treating everyone
who qualifies for either lipid lowering medication, blood
pressure medication, or both. We also estimated the
social value for three potential targeted approaches:
treating all with a measure of LDL-C >130 mg/dL and/
or SBP >140 mmHg who had at least one other CVD risk
factor; treating all with a measure of LDL-C >130 mg/dL
and/or SBP > 140 mmHg and ages 55 years or older; and
treating all with a measure of LDL-C >130 mg/dL and/or
SBP > 140 mmHg and ages 65 years or older.
We found that treating people with at least one other
CVD risk factor with a combination of blood pressure
lowering medication and lipid-lowering therapy would
result in 4.3 billion person-years of treatment over the
15 year period, a net cost to the Chinese healthcare sys-
tem of $563 billion and a value of life years saved of
$1349 billion. The net social value, or social surplus, that
results would be $787 billion, yielding a surplus to bene-
fit ratio of 58 %. Treating only people over 55 years of
age would result in 2.8 billion person-years of treatment,
net cost to the Chinese healthcare system of $309 bil-
lion, and a value of life years saved of $1240 billion. This
would yield a social surplus of $932 billion, yielding a
surplus to benefit ratio of 75 %. Finally, treating only
people over 65 years of age would generate 1.4 billion
person-years of treatment, a net cost to the Chinese
healthcare system of $95 billion, and a value of life years
saved of $841 billion, a social surplus of $747 billion,
and a surplus to benefit ratio of 89 % (Fig. 5).
Discussion
Cardiovascular disease and other non-communicable
diseases play an increasingly important role in the
disease burden faced by a number of emerging market
societies, including China. For example, CVD now ac-
counts for more deaths in China than any other illness.
While the transformation appears remarkable at first
glance, China now finds itself on a well-worn path famil-
iar in other developed economies. Increasingly sedentary
lifestyles and dietary changes, combined with progress in
the treatment of infectious disease, frequently increase
the burden of CVD. Historically this transition begins
with a greater prevalence of hypertensive heart disease
and hemorrhagic stroke and evolves into a second stage
characterized by rising rates of ischemic heart disease,
diabetes, hyperlipidemia, and obesity. China is thought
to be somewhere between these two stages, with CVD
burden dominated by stroke over the past decade and
CHD now emerging as a parallel threat.
The incidence of CVD in China is expected to con-
tinue to grow, with one study suggesting that annual
CVD events will increase more than two-fold between
2010 and 2030 based on population growth alone. When
factors such as projected trends in blood pressure and
cholesterol are accounted for, annual CVD events are
expected to grow by an additional 23 %. These estimates
imply an annual increase of 21.3 million CVD events
and 7.7 million CVD-related deaths by 2030 [50]. These
trends are mirrored in the results of the burden estima-
tion part of our study.
To validate our model, we compared the outputs from
our baseline year against other peer-reviewed studies
Table 3 Estimates of number of AMIs, strokes, and CVD deaths









Total population 9,718,958 7,822,617 3,359,026
At least one other
CVD risk factor
8,861,135 6,955,115 3,034,802
> 55 years 7,847,580 6,798,342 3,039,769
> 65 years 5,330,256 5,124,158 2,497,361
Blood pressure management
Total population 12,690,319 24,090,474 7,322,172
At least one other
CVD risk factor
11,705,084 21,439,156 6,570,986
> 55 years 10,850,141 21,062,444 6,822,105
> 65 years 7,150,355 14,382,099 5,453,613
Lipid and blood pressure
management
Total population 19,621,753 29,640,863 9,713,259
At least one other
CVD risk factor
18,020,822 26,371,553 8,730,106
> 55 years 16,431,006 25,878,475 8,982,422
> 65 years 10,932,970 18,007,273 7,226,067
The three targeted approaches to lipid and blood pressure management include
(i) treating all those with hyperlipidemia with a measure of LDL-C >130 mg/dL
and/or hypertensives with SBP > 140 mmHg who had at least one other CVD risk
factor; (ii) treating all with a measure of LDL-C >130 mg/dL (and/or SBP >140
mmHg) and ages 55 years or older; and (iii) treating all with a measure of
LDL-C >130 mg/dL (and/or SBP >140 mmHg) and ages 65 years or older. Data
are based on authors’ calculations
AMI acute myocardial infarction, CVD cardiovascular disease
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that look at the burden of CVD in China. Yang et al.
(2013) use results from the recent Global Burden of
Disease study and suggest CHD (or ischemic heart
disease) deaths of just under one million in 2010, with
various types of CVD deaths of over 3 million [1]. Both are
shown to have risen rapidly since 1990 at around 3–6 %
annually, which would suggest approximately 1.1 million
deaths in 2013. Our model started with an estimate of
CVD deaths of 1,185,064 in 2013, well within the range
seen in the literature. In terms of morbidity, Moran et al.
(2010) suggest that we should expect 3.2 million AMIs
in 2010 and rising [50]. We estimated 3.7 million AMIs
for 2013.
To determine the potential value of future policies in
controlling the inevitable rise of CVD burden in China
and the resulting costs to the healthcare system and the
population, it is important to estimate the potential size
of this burden over time and to highlight key drivers of
this growth. The World Bank estimates that reducing
CVD mortality by 1 % per year for 2010–2040 would
save China more than $10.7 trillion, or 68 % of China’s
real GDP in 2010 [51]. Our work highlights, more spe-
cifically, the potential value of intervening in just two of
the CVD risk factors and predicts a net social value of
up to $1.5 trillion between 2016 and 2030.
Our study has a number of limitations. We did not
explicitly differentiate between primary and secondary
prevention in the empirical model. Because our model
relies on a regional risk data set that was taken from
studies covering a population of almost 2 billion people,
it may not be a perfect fit to the Chinese population and
should be viewed as a meta-level model. Although major
risk confounders have been stratified, there are likely to
be sources of heterogenetiy that have not been included.
Fig. 2 Estimates of total number of AMIs under different treatment policy scenarios (2016–2030). Notes: Data are based on authors’ calculations.
AMI = acute myocardial infarction
Fig. 3 Estimates of total number of strokes under different treatment policy scenarios (2016–2030). Notes: Data are based on authors’ calculations
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We also focused on the potential value attributable to
averted deaths, which may underestimate the social value
of CVD prevention, as it excludes the considerable morbid-
ity burden from CVD. Counter to this, although a limita-
tion, we have excluded any adverse effects from statins and
blood pressure medication since studies have suggested that
the adverse effects of both sets of drugs, while noticeable,
are significantly outwieghed by the benefits [52, 53]. Lastly,
due to limitations on available data, many of our efficacy
and risk inputs were not specific to the Chinese population.
We focused on identifying parameters estimated with high
levels of statistical significance, prioritized meta-analyses
over individual trial results, and used the East Asia region-
specific risk data from GloboRisk.
Fig. 4 Estimates of total number of CVD deaths under different treatment policy scenarios (2016–2030). Notes: Data are based on authors’ calculations
Fig. 5 Estimates of net social value under three targeted approaches to lipid and blood pressure management. Notes: The three targeted approaches
to lipid and blood pressure management include (i) treating all those with hyperlipidemia with a measure of LDL-C >130 mg/dL, and/or hypertension
with SBP > 140 mmHg who had at least one other CVD risk factor; (ii) treating all with a measure of LDL-C >130 mg/dL (and/or SBP > 140 mmHg) and
ages 55 years or older; and (iii) treating all with a measure of LDL-C >130 mg/dL (and/or SBP > 140 mmHg) and ages 65 years or older. Data are based
on authors’ calculations. The assumed value of a life year in China is estimated at $13,408 (twice the GDP per capita in 2015). Approximately 23 % of
the above estimates accrued between 2016 and 2020 and 55 % accrued between 2016 and 2025
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Two particular aspects of the social value of reducing
the burden of CVD in China have been touched upon
elsewhere. A recent World Bank report [51] suggested
that the combination of the low reproductive rate over the
past two decades and the fast aging of the population will
likely place a major strain on China’s workforce in the
next 20 years. Considering that, approximately half of all
CVD burden is currently within the population under 65
years of age, failing to prioritize CVD control which could
severely impact the quantity and quality of human capital
available to China in the coming decades.
Conclusion
Cardiovascular disease is quickly becoming the dominant
cause of preventable death in emerging economies, and
the speed of its future growth is a rising concern, espe-
cially in China where the impact of rapid economic
growth over the past two decades is now seen in a swift
health burden transition. Using evidence on the impend-
ing demographic changes to China’s population as well as
empirical evidence suggesting the impact of economic
growth on future prevalence of major CVD risk factors,
our model predicted that the burden of CVD in China will
grow rapidly in the next 15 years if left unchecked. Our
study underscored this risk to the Chinese population.
In addition, we modeled the likely impact of taking an
early and aggressive stance on managing hyperlipidemia
along with blood pressure, the potential surplus that
would accrue to the health system, and the value of
intervening to society. At a time when the Chinese gov-
ernment is taking steps towards a more systematic ap-
proach to health care delivery, primary and secondary
prevention of CVD should be high on the agenda.
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